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ABSTRACT Measles virus (MV) infection is undergoing resurgence and remains one
of the leading causes of death among young children worldwide despite the avail-
ability of an effective measles vaccine. MV infects its target cells by coordinated ac-
tion of the MV hemagglutinin (H) and fusion (F) envelope glycoproteins; upon
receptor engagement by H, the prefusion F undergoes a structural transition, ex-
tending and inserting into the target cell membrane and then refolding into a post-
fusion structure that fuses the viral and cell membranes. By interfering with this
structural transition of F, peptides derived from the heptad repeat (HR) regions of F
can inhibit MV infection at the entry stage. In previous work, we have generated po-
tent MV fusion inhibitors by dimerizing the F-derived peptides and conjugating
them to cholesterol. We have shown that prophylactic intranasal administration of
our lead fusion inhibitor efficiently protects from MV infection in vivo. We show here
that peptides tagged with lipophilic moieties self-assemble into nanoparticles until
they reach the target cells, where they are integrated into cell membranes. The self-
assembly feature enhances biodistribution and the half-life of the peptides, while in-
tegration into the target cell membrane increases fusion inhibitor potency. These
factors together modulate in vivo efficacy. The results suggest a new framework for
developing effective fusion inhibitory peptides.
IMPORTANCE Measles virus (MV) infection causes an acute illness that may be asso-
ciated with infection of the central nervous system (CNS) and severe neurological
disease. No specific treatment is available. We have shown that fusion-inhibitory
peptides delivered intranasally provide effective prophylaxis against MV infection.
We show here that specific biophysical properties regulate the in vivo efficacy of MV
F-derived peptides.
KEYWORDS Viral fusion inhibitor, self-assembling nanoparticles, lipid tagging,
membrane insertion
Infection by measles virus (MV) remains one of the leading causes of death amongyoung children worldwide (1) despite the availability of an effective measles vaccine.
MV was considered to be eliminated in the United States in 2000 (defined as interrup-
tion of continuous transmission lasting 12 months) (2). However, the resurgence of
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measles in the United States in 2014 and 2015 made it clear that measles infection has
yet to be eradicated. In 2014, MV caused 114,900 deaths, globally mostly in children
under 5 years. As reported by the World Health Organization (WHO), the United States
experienced more cases in 2014 than in any year since 1996 (3), and MV was added to
the NIAID’s list of emerging viruses. The 2015 outbreak that began at Disneyland in
Southern California further highlights our vulnerability to MV, especially in situations
where herd immunity has declined. Outbreaks in the United States are often attributed
to the presence of unvaccinated individuals; however, a significant number of cases
occur in previously vaccinated people (4, 5).
MV infection starts in the respiratory tract, where alveolar macrophages and den-
dritic cells are the primary CD150-expressing targets (6–9). The binding of the MV
receptor binding protein hemagglutinin (H) to CD150, accompanied by membrane
fusion mediated by the MV fusion (F) protein, leads to infection of these cells. The first
MV-infected cells then transmit the virus to bronchus-associated lymphoid tissues
and/or draining lymph nodes, where the virus proliferates in B and T lymphocytes
(which also express CD150) and viremia ensues (6, 10). The adherent junction protein
PVRL4 (or nectin-4) (11–15) MV receptor on the basolateral surface of the respiratory
epithelial cells has been implicated in viral transmission at later stages of pathogenesis
but is likely not involved at the early stages (10, 14).
Coordinated action of the MV H and F envelope glycoproteins is essential for viral
entry. The trimeric F structure is kinetically trapped in a metastable conformation and
primed for fusion activation upon engagement of H by a cell surface receptor, either
CD150 (SLAM) or nectin-4 (11–17). After receptor engagement by H, the prefusion F
undergoes a structural transition, extending and inserting its hydrophobic “fusion
peptide” into the target cell membrane. The entry process is thought to be driven by
the refolding of F into a six-helix bundle postfusion structure that brings together and
fuses the viral and cell membranes (18–25). Peptides derived from the C-terminal
heptad repeat (HRC) regions of F can potently inhibit MV infection at this early stage
(26–28) by interfering with this structural transition of F. We have shown that the
efficacy of F-inhibitory peptides is modulated by the H-receptor interaction; the peptide
concentrations that inhibits fusion by 50% and 90% (IC50 and IC90, respectively) are
increased in the presence of stronger H-receptor interaction (29). These relationships
between fusion activation, receptor engagement, and inhibition are relevant to antiviral
design and help explain some of the previous hurdles to developing effective entry
inhibitors for MV (30–32). We contend that the dimeric form of the prototype lipid-
conjugated fusion inhibitor (HRC4, shown in Table 1), either by targeting multiple
N-terminal heptad repeat (HRN) domains and/or by targeting the HRN at multiple sites,
has partially overcome this MV-specific issue, as evidenced by its in vivo efficacy (29).
We show here that the addition of lipophilic moieties imparts self-assembling
properties to fusion-inhibitory peptides. The kind of lipophilic moiety and the peptidic
region both contribute to a balance between self-assembly and disaggregation. We
propose that the propensity of a peptide to desegregate in the proximity of its target
cell correlates with its in vivo efficacy. We speculate that an optimal balance between
self-assembly and membrane integration regulates in vivo efficacy. Our results provide
a framework for designing effective antiviral fusion-inhibitory peptides. This strategy, in
which advances in nanotechnology are integrated with an understanding of the
TABLE 1MV HRC-derived peptides
MV peptide Sequence
HRC1a Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(CH2CONH2)-NH2
HRC2a Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(PEG4-Chol)-NH2
HRC3a [Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(MAL-PEG11)-NH2]2
HRC4a [Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(MAL-PEG4)NH2]2-Chol
HRC5 Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(PEG4-Toc)-NH2
HRC6 [Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-GSGSG-C-(MAL-PEG4)NH2]2-Toc
aDescribed in references 29 and 45.
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molecular mechanisms of viral entry and its in vivo inhibition, will permit a streamlined
antiviral approach to existing and emerging viral pathogens.
RESULTS
Lipid-conjugated inhibitory peptides self-assemble into nanoparticles. Peptides
may exhibit high amphipathicity and a tendency to self-associate into higher-order
structures, depending on the nature of their amino acid sequence and folding. Chem-
ical conjugation of peptides with highly hydrophobic molecules such as cholesterol
(Chol) and tocopherol (Toc) might affect peptide stability in aqueous solution. The MV
HRC-derived fusion-inhibitory peptides described here (HRC1 to -6) (Table 1) contain a
hydrophobic lipid binding domain connected to the virus-specific amino acid sequence
by a flexible hydrophilic polyethylene glycol (PEG) linker, features resembling the
building blocks of self-assembling nanoparticles such as albumin polymer-conjugated
nanocarriers (33). We had hypothesized that the lipid-tagged peptides disperse into the
target cell membrane (34) and therefore asked whether they self-assemble into nano-
particles (35, 36). Self-assembling properties could have implications for the peptides’
mode of antiviral action. We propose that the in vivo antiviral activity we observed
results from a combination of self-aggregation properties and integration into the
target cell membrane, and we tested this hypothesis experimentally. We explored the
relationship between physicochemical properties, aggregation, and membrane inser-
tion kinetics of the conjugated peptides to identify features that correlate with inhib-
itory efficacy in vitro and in vivo. Specifically, the tendency of HRC peptides to
self-assemble, the peptides’ aggregation profiles, and their target membrane desegre-
gation were assessed.
As an initial screen to examine the tendency of each peptide to self-assemble in
aqueous solution, an 8-anilinonaphthalene-1-sulfonic acid (ANS) fluorescence emission-
based methodology was used. ANS is a small probe (300 Da) which nonspecifically
interacts with hydrophobic sites resulting from molecular aggregation (37). Upon
binding to these sites, the probe fluorescence emission maximum max undergoes a
blue shift and an intensity (IF) increase that correlates with peptide aggregation. In the
presence of ANS, increasing concentrations of peptides HRC2, -4, -5, and -6 induced
max blue shifts (Fig. 1A). The maximum observed shift was similar among peptides,
averaging 65 ( 5) nm, and was constant for concentrations above 15 M. Above this
concentration the population of emitting molecules is predominantly bound to peptide
aggregates. An increasing IF value as a function of the HRC2, -4, -5, and -6 peptide
concentrations was also detected (Fig. 1B). At 40 M each peptide, the ANS [IF()] was
over 15-fold higher than the control value obtained in the absence of peptide. In the
presence of the HRC1 and -3 peptides (without a lipid moiety), no significant ANS
fluorescence emission variation was observed. These results suggest that peptides
HRC2, -4, -5, and -6 aggregate in solution, forming local hydrophobic sites, while
peptides HRC1 and -3 do not self-assemble.
Given the potential of peptides HRC2, 4, -5, and -6 to self-assemble in aqueous
solution, the resulting aggregates’ dimensions were determined using dynamic light
scattering (DLS). This technique is capable of nanoscale particle hydrodynamic radius
(RH) measurements in solution and is suitable for peptide/protein assays (38). The
number-averaged size distribution profiles of each peptide were used to retrieve the
modal RH at different peptide concentrations (Fig. 2). Peptides HRC2 and -5 displayed
number-averaged particle RHs between 31 and 47 nm and between 41 and 56 nm,
respectively, irrespective of the peptide concentration used. Peptides HRC4 and -6
showed similar average particle RH values between 27 and 82 nm, but these values
were significantly influenced by increasing peptide concentrations. These observations
indicate that the conjugated HRC peptides self-assemble into stable aggregates in
solution, even at low concentrations. For the peptides in the monomeric form, similar
aggregates sizes were obtained even at different concentrations, which is indicative of
organized aggregates with well-defined structures. In dimeric form, the peptides seem
to aggregate into larger particles in a concentration-dependent fashion, which is
Lipid-Driven Membrane Association of Fusion Inhibitors Journal of Virology
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indicative of loose aggregates of unspecific structure. Whether Chol or Toc was used as
the lipid conjugate did not significantly affect the peptide’s aggregation behavior.
Insertion of lipid-targeted peptides in lipid membranes. Strategic conjugation of
HRC peptides with either Chol or Toc moieties has considerably improved the efficacy
FIG 2 Aggregation of the MV HRC peptides evaluated by dynamic light scattering (DLS). DLS particle size determination of
aggregated HRC2 (black), -4 (red), -5 (blue), and -6 (gray) peptides is shown. Size distribution profiles based on particle number
were obtained from DLS autocorrelation functions. (A) Representative profile obtained for peptide HRC6 at 10 M. (B) RH values
were retrieved from the statistical mode (dark gray bar in panel A) of each peptide distribution at final concentrations, [HRCX].
The mean RH values were compared using Tukey’s method to test pairwise differences between concentrations of the same
peptide (comparison to 1 M is shown). The presented results are the averages of three independent replicates. Error bars
represent the SD. n.s., not significant; *, P  0.01; **, P  0.001; ***, P  0.0001.
FIG 1 Aggregation of the MV HRC peptides evaluated by ANS fluorescence properties. ANS fluorescence
emission properties are an indicator of peptide aggregation in aqueous solution. ANS (12.8 M) was
titrated with small volumes of each peptide up to final concentrations, [HRCX], where X represents the
number of each peptide (HRC1, white circles; HRC2, red circles; HRC3, blue circles; HRC4, green circles;
HRC5, gray circles; HRC6, black circles). The fluorescence maximum emission wavelength (max) (A) and
the spectrum integral {[IF()]} (B) were plotted as a function of [HRCX]. Panels A1 and B1 correspond to
zoomed representations of the dashed areas in panels A and B, respectively. Results correspond to the
average of three independent replicates. Error bars represent the SD.
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of these peptides as antiviral fusion inhibitors (29). This effect was considered to be due
to enhanced peptide-membrane interactions, as previously suggested for other anti-
viral fusion inhibitor peptides (39, 40). Because of the hydrophobicity of the conjugated
groups, it is assumed that the peptides insert into the membrane surface. We propose
that this insertion correlates with the antiviral activity. In order to test this hypothesis,
we have used liposomes as membrane model systems for peptide-membrane interac-
tion studies. The precise lipid composition of the MV envelope remains poorly under-
stood, but it has been shown that MV virions emerge from high-cholesterol lipid raft
domains (41, 42). 1-Palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC)–Chol (2:1)
and POPC-Chol-chicken egg sphingomyelin (SM) (1:1:1) mixtures were used to mimic
the MV envelope composition and raft domains, while POPC was used to mimic the
cellular membrane composition. To study the peptide affinity toward different lipid
membrane compositions, we used large unilamellar vesicles (LUVs) containing the
lipophilic 4-(2-[6-(dioctylamino)-2-naphthalenyl]ethenyl)-1-(3-sulfopropyl)pyridinium inner
salt (di-8-ANEPPS) fluorescent probe. The probe’s excitation spectrum is sensitive to
variations in the membrane dipole potential and undergoes positive or negative
wavelength shifts as a result of protein/peptide interaction or insertion into the
membrane. These shifts can be converted to amplitudes in differential fluorescence
excitation spectra and analyzed through a semiquantitative ratiometric approach (43).
The peptides that induced a larger di-8-ANEPPS spectral shift in the presence of the
different lipid compositions were HRC2, -4, -5, and -6. This is evidenced by the decrease
in the normalized excitation intensity ratio (Rnorm) as a function of the peptide con-
centration (Fig. 3). The Rnorm values may be higher or lower than one, depending on
whether the spectral shift relative to the control spectra is to lower or higher wave-
lengths, respectively. HRC2 and -5, both conjugated monomers, seem to disturb
Chol-containing membranes with greater magnitude. The HRC4 and -6 peptides display
similar Rnorm values between the three lipid compositions. No changes in the di-8-
ANEPPS spectra were observed in the presence of the HRC1 and -3 peptides, even at
high concentrations. Note that it remains a formal possibility that these peptides
interact with lipids without significantly disturbing the membrane dipole potential. The
results suggest that Chol and Toc conjugation modified the peptides’ behavior toward
lipid membranes, allowing them to insert in lipid membranes and disturbing the
lipid-water dipole equilibrium.
In order to complement the di-8-ANEPPS fluorescence-based assays and further
understand how the HRC peptides interact and bind to lipid membranes, a surface
plasmon resonance (SPR) approach using Biacore technology was applied. This flow-
based technique allows real-time detection of bound molecules on a small unilamellar
vesicle (SUV)-covered surface (44). Using the same lipid formulations that were used for
the di-8-ANEPPS assay, kinetic profiles (sensorgrams) of each peptide binding to SUV
surfaces were acquired. Each sensorgram is composed of sequential binding and
unbinding phases, corresponding to the sample injection over the lipid vesicle surface
followed by the removal of bound sample molecules through solvent flow, respectively.
Based on the maximum peptide binding and SUV deposition response, the respective
peptide-to lipid [mol(P)/mol(L)] ratios were calculated and plotted as a function of the
injected peptide concentration (Fig. 4). HRC4 and -6 showed the highest binding
toward each lipid composition tested, followed by HRC2. On the other hand, HRC1, -3,
and -5 showed very low binding affinity to all the different lipid compositions used. In
general, all the HRC peptides showed greater affinity toward deposited POPC SUVs.
From the unbinding data for the HRC peptides (t  200 s), we observed that HRC 2
remained tightly bound to the SUV surface after the binding phase. HRC4, -5, and -6
were removed from the surface slowly during unbinding, but faster than HRC2. HRC1
and -3 showed weaker binding and were quickly removed by solvent flow. Although
HRC1 and -3 seem to transiently interact with lipids, Chol and Toc conjugation
considerably improved the membrane interaction properties of the HRC peptides.
Biacore SPR sensorgrams indicate that dimers have faster binding kinetics and achieve
higher mol(P)/mol(L) values than the respective monomers. Additionally, our results
Lipid-Driven Membrane Association of Fusion Inhibitors Journal of Virology
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suggest that a fraction of conjugated peptides remains bound to lipid membranes with
increased stability, even after the unbinding phase.
Lipid-conjugated inhibitory peptides inhibit cell-to-cell fusion. We have previ-
ously identified a strong correlation between efficiency of inhibiting cell-to-cell fusion
in vitro and in vivo potency (45). We have attributed the enhanced in vivo efficacy of
specific peptides to their membrane insertion properties identified in vitro (34). Here we
describe the biophysical properties of monomeric and dimeric peptides conjugated
with different lipophilic moieties and peptide valencies, which resulted in different
propensities for membrane insertion or self-association. For the dimeric peptides, these
properties are also concentration dependent. We therefore asked which properties
FIG 3 Peptide-membrane interaction studies by ANEPPS excitation spectrum shift. Ratiometric analysis of di-8-ANEPPS excitation spectrum
deviations induced by HRC peptide-membrane interactions is shown. Discrete concentrations of HRC1 to -6 (A to F, respectively) were incubated
with di-8-ANEPPS-labeled POPC (white circles, black line), POPC-Chol (2:1) (red circles, red line) and POPC-Chol-SM (1:1:1) LUV (blue circles, blue
line). Intensity ratios (Rnorm) were calculated based on the respective differential excitation spectrum peak wavelengths and normalized to the
control in the absence of peptide. For each ratiometric graph, the respective di-8-ANEPPS differential excitation spectrum obtained at 40 M
peptide concentration is shown as a representative example. These were obtained by subtraction of di-8-ANEPPS normalized control spectra from
the normalized spectra in the presence of each peptide. Ratiometric results correspond to the average of three independent replicates. The
presented differential spectra are one of three independent replicates. Error bars represent the SD.
Figueira et al. Journal of Virology
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FIG 4 Sensorgram maximum binding response versus peptide concentration. SPR time-resolved sensorgrams of HRC1 to -6 (A to F) interacting
with deposited POPC (left sensorgrams), POPC-Chol (2:1) (center sensorgrams), and POPC-Chol-SM (1:1:1) SUV (right sensorgrams). Discrete
HRC-peptide concentrations were injected over the deposited vesicles at a 5-l/min flow speed for a total of 200 s. Each sample was allowed a
600-s unbinding time. (G) Concentration-dependent SPR peptide-to-lipid ratios [mol(P)/mol(L)] of HRC1 (white circles), -2 (red circles), -3 (blue
circles), -4 (green circles), -5 (gray circles), and -6 (black circles) peptides interacting with deposited POPC (left), POPC-Chol (2:1) (center), and
POPC-Chol-SM (1:1:1) SUV (right). Peptide binding and SUV capture response values were retrieved from individual sensorgrams at specific
reporting time points. mol(P)/mol(L) values were calculated based on the relationship 1 RU 1 pg/mm2 of bound peptide or lipid and plotted
as a function of the injected peptide concentration. Error bars represent the SD of two independent replicates.
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best correlate with fusion-inhibitory activity of the peptides studied here. We
considered that the dimeric form of the fusion inhibitor peptides (HRC3, HRC4, and
HRC6), by simultaneously targeting multiple N-terminal heptad repeat (HRN) do-
mains, may have an inherent advantage over the monomeric peptides. However, the
presence of the two peptidic sequences alters the membrane association. To determine
how these factors affect in vitro potency we measured fusion inhibition using a
semiquantitative -galactosidase (-gal) complementation assay (46). This assay mea-
sures the fusion of cells that express viral envelope glycoproteins (MV IC323 H/F) with
cells that express the MV receptor SLAM or nectin-4 (Table 2). Table 2 shows the
peptide concentrations that blocked 50% (IC50) and 90% (IC90) of fusion. As anticipated,
the addition of a lipophilic moiety increased the antiviral potency of the HRC peptides
compared to that of the untagged peptides. However, the difference in potency between
the monomeric/dimeric peptides with Toc was not as dramatic as for the Chol-tagged
peptides. When fusion-inhibitory potency was assessed using CD150 as a receptor on
the target cells, the fusion-inhibitory potency was higher than that with target cells
expressing the nectin-4 receptor. The H–nectin-4 receptor interaction is stronger than
the interaction between H and CD150 (11–15), and the data presented here are in
agreement with our previous findings that correlate peptide efficacy versus F protein-
mediated fusion to the strength of interaction between the cellular receptor and the
receptor binding protein (H) (29). The most potent peptide under these conditions
remains the dimeric peptide conjugated to Chol.
Lipid-targeted inhibitory peptides cross the HAE differentially. To assess the
potential for lung delivery of the lipid-conjugated HRC peptides, we used an ex vivo
mucosal tissue model consisting of normal, human-derived tracheal/bronchial epithe-
lial cells that have been cultured to form a highly differentiated model that closely
resembles the human airway epithelium (HAE) tissue of the respiratory tract. We have
used HAE for evaluating entry inhibitors (47–51). In previous work, we found that the
monomeric (HRC2) and dimeric (HRC4) peptides conjugated to cholesterol both reach
the basolateral face in similar concentrations (29). Based on the data in Fig. 4, we
hypothesized that the HRC6 peptide may remain localized on the luminal side of the
lung with minimal spillover into the circulation. If this hypothesis is correct, then the
peptides, added to the apical surface, would remain on the apical surface of the airway
epithelium with minimal transfer to the basolateral lumen.
HRC4 and HRC6 peptides were added to the apical side of the HAE to determine
when and at what concentration they would reach the basolateral lumen (Fig. 5). The
amount of peptide (20 l at 250 M) was sufficient to reach concentrations of 5 M if
added directly to the basolateral reservoir (which contains 1 ml of medium). The
presence of peptide basolaterally was detected by enzyme-linked immunosorbent
assay (ELISA) at 8, 24, 48, and 72 h after treatment, with peak concentrations for MV
HRC4 (0.02 M) at 24 h, indicating that both peptides reach the basolateral reservoir.
Detectable levels of HRC6 peptide were observed only at 48 and 72 h and at two-log-
lower concentrations. The results indicate that the biophysical properties imparted by
the lipophilic (Toc) moiety altered the peptide permeability to the HAE.
TABLE 2 In vitro efficacy of MV HRC-derived peptides
MV peptide
Fusion inhibitiona at 4 h
SLAM Nectin-4
IC50 (M) IC90 (M) IC50 (M) IC90 (M)
HRC1 10 10 10 10
HRC2 0.05 0.01 10 4.6 0.6 10
HRC3 ND ND ND ND
HRC4 0.01 0.005 0.05 0.1 0.04 0.5
HRC5 0.25 0.09 1 1.4 0.5 10
HRC6 0.30 0.10 1 1.3 0.5 10
aValues are means and standard deviations. ND, not determined.
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Intranasally delivered lipid-conjugated dimer peptides inhibit MV infection in
vivo. MV infection in cotton rats (CR) is a natural infection model (52). MV replicates in
CR lung tissue with peak titers occurring on day 4 or 5, and infection is overcome by
day 8. We have previously shown that HRC2 and HRC4 delivered intranasally (i.n.)
remain in the lungs (29, 45). Here we compared the biodistributions of HRC4 and HRC6
in the CR. Peptides were delivered intranasally (6 mg/kg, 3 animals per peptide), and
the animals were euthanized 8 h after administration. Serum, lungs, and brain were
collected for each animal, and peptide concentrations were measured by ELISA (29, 45)
(Fig. 6). HRC4 and HRC6 remain in the lungs after intranasal delivery (HRC4, 0.44 M;
HRC6, 2.00 M). Following i.n. delivery the serum concentrations of HRC4 and HRC6
were 0.03 M and 0.003 M, respectively. Thus, HRC4 crosses the airway epithelium of
the CR in vivo, while HRC6 remains localized to the lungs. HRC4 attains a brain
concentration of 0.002 M; in contrast, HRC6 is below the limit of detection in brain
tissue. The finding that most of the Toc-conjugated peptide (HRC6) that is delivered i.n.
remains localized in the respiratory tract suggests that this peptide could be used for
i.n. prophylaxis against viruses transmitted via the respiratory route.
The peptides that were delivered intranasally have no detectable undesirable effects
in the cotton rats. HRC6 (dimeric form conjugated with Toc) reached the highest lung
concentration (Fig. 6) (29), with minimal presence in the serum and none detectable in
the central nervous system (CNS). In HAE (Fig. 5), apically delivered HRC6 is found in the
basolateral reservoir only 72 h after administration (and at a 10-fold lower concentra-
tion than the HRC4 cholesterol-conjugated peptide), indicating that the dimer with Toc
is retained on the apical side of the human airway, in agreement with the biodistribu-
tion results. Our data indicate that the lipid moiety greatly influences in vivo biodistri-
bution.
We next assessed the antiviral prophylactic efficacy of the peptides after intranasal
delivery in the CR. We compared the two peptides whose biodistribution was assessed
as described above (HRC4 and HRC6), and we added the other HRC peptides (Table 1)
as controls (29, 50, 53).
The animals were given the fusion-inhibitory peptides i.n. twice (5 mg/kg each) at
24 and 12 h before infection (Fig. 7). Four days after infection, the viral titer in the lungs
of untreated animals was 104 50% tissue culture infectious doses (TCID50)/g lung tissue
(1  103); the HRC5 peptide-treated animals had viral titers with no significant
differences from those of the untreated animals (Fig. 7), despite the in vitro potency of
this peptide (Table 2). After prophylaxis with the MV HRC1-derived peptides, the titer
was reduced to 9 103 TCID50/g lung tissue (2 103), and after prophylaxis with the
other MV-derived peptides (HRC2, HRC3, HRC4, and HRC6), no MV virus at all was
detected in the lungs. Statistical analysis using a Mann-Whitney U test (***, P  0.001)
revealed the strong significance of the MV peptides’ inhibitory effect compared to
either the untreated group or the group treated with HRC5-derived peptides. The i.n.
FIG 5 Peptides cross the human airway epithelium (HAE). Medium (liquid interface) was collected at each
time point for quantification of peptide by ELISA. Kinetic analysis (ELISA) of the peptide concentration in
the liquid reservoir of the culture reflects minimal transit through the HAE for HRC4 (A) and HRC6 (B).
Lipid-Driven Membrane Association of Fusion Inhibitors Journal of Virology
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delivered MV peptides (with the exception of the monomeric untagged HRC1 and the
Toc-tagged HRC5) efficiently blocked MV infection in the CR.
We previously showed that i.n. delivery of MV HRC4 peptides alone is sufficient to
protect from fatal measles encephalitis. We now assessed whether the HRC5 and HRC6
peptides protect mice from a lethal MV challenge. Animals (SLAMIFNARKO mice as
used previously [29, 45]) were treated with HRC5 or HRC6 intranasally (6 mg/kg) at 24
h and 4 h before infection (10 l of peptide-containing vehicle). A mock-infected group
received vehicle at the same time. Animals were followed for 28 days after the infection.
The survival median for the mock-infected group was 9.5 days. For the animals treated
with HRC5, the survival median was 18 days (***, P  0.0007; Mantel-Cox test); the
peptide significantly enhanced the median survival time but did not fully protect. The
i.n. administration of HRC6 completely protected SLAMIFNARKO mice from fatal CNS
infection. (Fig. 8).
DISCUSSION
Measles virus (MV) induces respiratory infection and can cause a profound suppres-
sion of the immune system that may permit opportunistic infections. CNS complica-
FIG 6 Bioavailability of MV HRC-derived peptides in cotton rats at 8 h after intranasal administration.
Animals were inoculated with 100 l per nare (200 l total, 6 mg/kg, 3 animals) and then were
euthanized 8 h after administration. Peptide concentrations in serum, lung, and brain were measured by
ELISA (shown in log scale as in reference 29). Data are presented as an average from three animals  SD.
Data are on a log scale.
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tions of MV infection may occur soon after infection in the case of acute encephalo-
myelitis or years after infection as a result of viral persistence in subacute sclerosing
panencephalitis (SSPE) and progressive infectious encephalitis or measles inclusion
body encephalitis (MIBE). There are no specific therapies for acute complications of MV
or for persistent MV infections (54–58). While vaccine compliance is a major problem in
MV eradication, important groups of vulnerable patients cannot be protected by
vaccination, and vaccine failure also contributes to the susceptible population (59–65).
A 2011 outbreak in New York City originated with a fully vaccinated young adult and
spread to several vaccinated individuals with documented markers of immunity. Of the
98 cases of MV in a 2011 measles outbreak in Canada, over half had received two doses
of MV vaccine (5, 60), and a significant number of vaccinated individuals contracted MV.
Up to 10% of people do not develop adequate protective antibodies (even after the
recommended two doses of vaccine), in contrast to the longstanding immunity elicited
by the natural infection. Vaccine-elicited immunity also likely wanes over time (63, 64,
66), and other factors can affect the response (65, 67). Antiviral prophylaxis could
protect unvaccinated individuals and prevent spread of virus in the population. In
infants under 9 months who do not respond to live attenuated MV vaccine and in
immunocompromised people, antiviral treatment could prevent severe consequences
of MV infection such as pneumonia and encephalitis. Since we expect our proposed
fusion-inhibitory peptide antivirals to be host factor independent, they will fill a specific
need for immunocompromised people at risk for MV infection who cannot be vacci-
nated or do not respond adequately to vaccine.
Our results point consistently to the conclusions that the most efficient antiviral
peptides are lipid-conjugated dimers, self-assemble into loose aggregates, and bind
FIG 7 Intranasal administration of MV-derived peptides protects cotton rats from MV infection. Cotton
rats (n  4) were infected i.n. with MV at 24 h after the first peptide treatment and were euthanized at
4 days postinfection. MV titration of lung homogenates showed that HRC2, HRC3, HRC4, and HRC6 block
infection in CR (***, P  0.001 by the Mann-Whitney U test). The limit of viral detection was 102 PFU/g.
FIG 8 Intranasal administration of MV-derived peptides protects transgenic mice from MV infection.
SLAMIFNARKO mice were infected intranasally with 104 PFU of MV G954. Animals were treated with
HRC5 or HRC6 intranasally (6 mg/kg) at 24 h and 4 h before infection. The mock-infected group only
received the vehicle at the same time. the Mantel-Cox test was used for the survival comparison analysis:
***, P  0.0007; *, P  0.0486 (between HRC5 and -6).
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extensively to membranes with high residence times. Several examples of engineering
polyvalent biological interactions have been described (68), and specific examples
where polyvalency increases the potency of fusion inhibitors (69, 70) or entry inhibitors
(17) have been reported. For HRC fusion inhibitors, dimerization/multimerization (45,
53) reduces the koff of the inhibitor-fusion protein complex formation in an effect that
has been termed the “avidity effect” (71). The lipophilic tag, on the other hand,
increases the kon for complex formation (45) by targeting the peptide to the cell
membrane where the virus fuses, increasing the local peptide concentration. We asked
whether the two modifications would work in concert, and indeed we demonstrate that
the interplay between the lipid moiety and the peptidic portion affects two important
properties of the peptides: self-assembly and membrane insertion. The hydrophobic
lipid moiety confers the self-aggregation properties; however, the membrane insertion
efficiency is influenced by the lipophilic moiety as well as by the peptide valency.
Dimeric peptides have steric restrictions to organized packing in a micelle-like arrange-
ment; monomeric peptides, however, do not have these restrictions and form orga-
nized micelle-like structures, which are stable in solution and therefore less prone to
interact with lipids. In fact we found that only the dimeric HRC4 and HRC6 peptides
insert efficiently into membranes, probably as a consequence of the assembly into
unstable aggregates in aqueous solution. In contrast to the other peptides, HRC4 and
HRC6 release slowly from membranes. We propose that these features of unstable
self-aggregation in solution combined with the capacity to insert in target cell mem-
branes with prolonged residence are key for the in vitro and in vivo potencies that we
observe for the dimeric lipid-conjugated peptides.
The lack of efficacy of the monomeric peptide conjugated to tocopherol (HRC5),
despite its in vitro potency, was a surprise. This peptide’s in vitro activity was similar to
that of the dimeric form (HRC6) (Table 2), but it was totally ineffective in cotton rats
(Fig. 7). However, HRC5 improved survival in the mouse model (Fig. 8). We suggest that
the specific biophysical properties of these two peptides (Fig. 4) led to different
membrane association, which may explain this difference in efficacy and the relative
inactivity of the monomer in vivo.
We considered the possibility that by targeting the lung, and particularly if in fact
lung-resident dendritic cells and alveolar macrophages are targeted, the peptides
might elicit an immune response that could affect their efficacy during subsequent
exposures to MV (72, 73). This would be a drawback for our proposed antiviral strategy,
which is designed for people who cannot be efficiently vaccinated. To explore this
possibility, we performed a preliminary experiment using MV HRC4 and the corre-
sponding human parainfluenza virus type 3 (HPIV3) F dimeric peptide as a control (29).
Cotton rats (CR) were administered either peptide i.n. for 3 weeks (5 times per week,
once a day), and sera were collected before and after peptide administration. After 3
weeks of treatment the animals—either peptide exposed, mock exposed, or exposed
to the control HPIV3-derived peptide—were kept for a week without treatment and
then challenged with virus. Pretreatment with HRC4 did not affect the efficacy of the
subsequent treatment in terms of reducing viral titers, and the sera tested negative for
the presence of antipeptide antibodies (data not shown). These preliminary results
suggest that several peptide administrations are possible without eliciting a detrimen-
tal antipeptide response.
In this study, we confirmed our previous findings that the fusion-inhibitory potential
of peptides is influenced by the nature of the target cell receptor (Table 2). To block
fusion between effector cells and target cells expressing nectin-4 requires more pep-
tides than when the target cells are expressing CD150. The affinity constant (Kd)
between CD150 and H has been reported to be 93.5 nM, and that between nectin-4 and
H has been reported to be 20.1 nM (11–15). Based on the different Kd values, we
inferred that peptide efficacy inversely correlates with H receptor affinity (e.g., nectin-4
versus CD150). We considered the possibility that the overall number of receptor
molecules present on the target cell surface may also alter the overall apparent avidity,
and this difference may also contribute to the different antiviral activities of the
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peptides. A potential role of avidity effect would be important for in vivo application of
the fusion inhibitor peptides, and therefore future work will assess the receptor
molecule density ex vivo and in vivo and correlate these values with antiviral potency.
The biophysical analyses described here can be used to guide the design of effective
antiviral fusion inhibitory peptides, in light of the coherent evidence here for the effects
on peptide efficacy of specific lipid conjugation, dimerization, self-assembly properties,
and membrane binding properties. These biophysical characteristics form a solid
background to the pharmacological and biological results, correlating well with in vivo
efficacy of the antiviral peptides for preventing or treating MV infection. By modulating
the lipid moiety and/or the PEG linkers, we improved peptide antiviral potency through
modulation of aggregation and lipid affinity, and we suggest that these properties may
also be used to regulate in vivo biodistribution. The data presented here should in the
future be confirmed in animal models that more closely reflect human infection.
Nonhuman primates (NHP) mimic several aspects of MV infection in humans (6, 74), and
future work will include assessment of optimized fusion inhibitors in NHP. This ap-
proach should readily translate into a streamlined development plan for safe and highly
effective fusion inhibitors that can be aerosolized/inhaled for anti-MV prophylaxis in
high-risk unvaccinated populations and vulnerable hosts.
MATERIALS AND METHODS
Chemicals and reagents. The lipids 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC) and
chicken egg sphingomyelin (SM) were purchased from Avanti Polar Lipids (Alabaster, AL, USA), and
cholesterol (Chol) was purchased from Sigma-Aldrich (St. Louis, MO, USA). HEPES, NaCl, NaOH,
dimethyl sulfoxide (DMSO), ethanol, and chloroform (the last three with spectroscopic grade) were
obtained from Merck (Darmstadt, Germany). The fluorescent probes 8-anilino-1-naphthalenesulfonic acid
(ANS) and 4-(2-[6-(dioctylamino)-2-naphthalenyl]ethenyl)-1-(3-sulfopropyl)pyridinium inner salt (di-8-
ANEPPS) were purchased from Sigma. Biacore sensor chip regeneration reagents, namely, 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and methanol, were also purchased
from Sigma. Sodium dodecyl sulfate (SDS) was from GE Healthcare (Little Chalfont, United Kingdom).
Large unilamellar vesicle (LUV) and small unilamellar vesicle (SUV) suspensions were prepared as
previously described (75). The lipid mixture was first solubilized in chloroform in a round-bottom flask.
The solvent was evaporated under nitrogen flow until a thin lipid film was formed on the flask walls. The
lipid film was dried under vacuum overnight. A multilamellar vesicle (MLV) suspension was obtained after
rehydration with the sample buffer and a series of 10 freeze-thaw cycles. The MLV suspension was
extruded through a 50- or 100-nm-pore-size Nuclepore polycarbonate membrane purchased from
Whatman/GE Healthcare (Maidstone, United Kingdom) using a LiposoFast-Basic plus Stabilizer setup
from Avestin (Mannheim, Germany). This allowed the reorganization of MLVs into SUVs or LUVs,
respectively. POPC, POPC-Chol (2:1), and POPC-Chol-SM (1:1:1) liposomes were prepared.
Plasmids and reagents. The genes of MV IC323 wild-type (wt) H and wt F were codon optimized,
synthesized, and subcloned into the mammalian expression vector pCAGGS. The constructs for SLAM
and nectin 4 were commercially acquired.
Peptide synthesis. The measles virus (MV) HRC-derived fusion inhibitor peptides (HRC1 to -6) (95%
purity) were produced by standard 9-fluorenylmethoxy carbonyl (Fmoc) solid-phase methods. The lipid
moieties were attached to the peptides via chemoselective reaction between the thiol group of an extra
cysteine residue, added C terminally to the sequence, and a bromoacetyl derivative of cholesterol/
tocopherol or a bis-maleimide functionalized cholesterol/tocopherol core, as previously described (24–
26). Peptides were stored as powder, and before use they were dissolved in DMSO to 5 mM stock
solutions that were kept at 	80°C for in vitro fusion assays. For biophysical studies, lyophilized peptides
were solubilized in 100% DMSO up to 40 mg/ml, sonicated in a water bath for 5 min, and stored at
	20°C. Working peptide samples at defined final concentrations were solubilized from stock solutions in
10 mM HEPES–150 mM NaCl buffer, pH 7.4. The final DMSO content was maintained at 2% (vol/vol) in
all experiments. Working peptide samples were sonicated in an ultrasonic bath for 2 to 5 min before use.
ANS fluorescence studies. For the peptide aggregation studies, a 12.8 M 8-anilinonaphthalene-
1-sulfonic acid (ANS) solution (A369 of 0.1 to avoid inner filter effects) was titrated with each HRC
peptide up to final concentrations between 0 and 40 M. For each sample, fluorescence emission spectra
were collected between 400 and 600 nm (excitation wavelength [exc]  369 nm) in an Edinburgh
FLS920 spectrofluorometer (Livingston, UK). Excitation and emission slits were 5 and 10 nm, respectively.
A 10-min incubation time was allowed before each measurement. The fluorescence emission intensity
values were corrected for dilution and background noise. The maximum emission wavelength, max, and
the spectrum integral, [IF()], were determined for each spectrum.
DLS. For dynamic light scattering (DLS), HRC peptide solutions with concentrations ranging from 1
to 30 M were prepared as described above and incubated at 25°C for 5 min before each measurement
of particle size. Measurements were performed in a Malvern Zetasizer Nano ZS (Worcestershire, UK) and
consisted of 15 individual runs, each corresponding to an averaged autocorrelation curve obtained from
at least 12 repeated sample scans. The diffusion coefficient (D) values were calculated from autocorre-
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lation curves using a CONTIN-like method (76). D values were used to determine number-averaged
hydrodynamic radius (RH) profiles through the Stokes-Einstein-Sutherland equation (77).
Membrane dipole potential sensing. To prepare di-8-ANEPPS-labeled LUVs, POPC, POPC-Chol (2:1),
and POPC-Chol-SM (1:1:1), lipid mixtures were cosolubilized with a di-8-ANEPPS solution in chloroform
for a final probe/lipid ratio of 1:200 (0.5 mol% di-8-ANEPPS relative to lipid). The subsequent LUV
preparation steps were carried out as described in “Chemicals and Reagents” above. The variations in
membrane dipole potential in the presence of the HRC peptides were monitored by di-8-ANEPPS
fluorescence excitation spectrum shifts. The emission wavelength was fixed at 670 nm to avoid
membrane fluidity artifacts (78), and fluorescence excitation spectra were collected between 380 and 580
nm in an FLS920 spectrofluorometer. Excitation and emission slits were 10 and 3 nm, respectively. Fixed
concentrations of each HRC peptide were incubated with 200 M labeled LUVs for 10 min before the
measurements were performed. Fluorescence excitation spectra were corrected for background noise.
The di-8-ANEPPS fluorescence spectra in the absence of peptide were used as controls. The normalized
intensity ratios (Rnorm) were used to quantitatively analyze di-8-ANEPPS spectral shifts (43).
Initially, the excitation intensity (Iexc) ratios (R) were calculated based on the relationship R 
[Iexc(a)]/[Iexc(b)], where a and b correspond to the wavelengths with the highest absolute intensity
difference in each differential excitation spectrum (spectrum maximum or minimum). For accurate
interpretation, a and b should be lower and higher than the maximum excitation wavelength,
respectively. R values were normalized to the respective excitation spectrum area.
SPR. For surface plasmon resonance (SPR), 10 mM HEPES–150 mM NaCl (pH 7.4) containing 2%
(vol/vol) DMSO was used as running buffer to match the peptide and lipid sample buffer composition.
Experiments were performed in a GE Healthcare Biacore X100. The system was primed at least three
times with running buffer before starting an experiment. The L1 sensor chip, which was designed for lipid
binding assays, was used in all experiments. The L1 sensor chip surface was first rinsed with three
injections of 20 mM CHAPS before starting an assay. To prepare the lipid surface, a 1 mM POPC,
POPC-Chol (2:1) or POPC-Chol-SM (1:1:1) SUV sample was injected over the sensor chip at a 2-l/min flow
speed for 2,400 s. Loosely bound vesicles were removed with a 36-s injection of 10 mM NaOH at 50
l/min. HRC peptide samples with concentrations between 1 and 30 M were injected over the
deposited SUV surface at a 5-l/min flow speed during 200 s. Each sample was allowed a 600-s
unbinding time after injection stopped. After each run, the sensor chip surface was regenerated with
sequential injections of 20 mM CHAPS (5 l/min for 60 s), 0.5% (wt/vol) SDS (5 l/min for 60 s), 10 mM
NaOH containing 20% (vol/vol) methanol (50 l/min for 36 s), and 10 mM NaOH (50 l/min for 36 s).
Response values were monitored to ensure effective surface regeneration. To analyze the SPR membrane
interaction data, the SUV deposition on the sensor chip surface and the response values for HRC peptide
binding to lipid were converted into units of moles per area and used to calculate the respective
peptide-to-lipid ratio [mol(P)/mol(L)]. To perform these calculations, we considered 1 response unit (RU)
to be approximately 1 pg/mm2 of peptide or lipid, as previously described in the literature (79). The SUV
deposition response values were collected from sensorgrams at 100 s after rinsing with 10 mM NaOH.
The HRC peptide binding response values were retrieved from sensorgrams at t  200 s of the binding
phase.
Transient expression of H and F genes. Transfections were performed in 293T cells according to
the Lipofectamine 2000 manufacturer’s protocols (Invitrogen).
Cells and viruses. 293T cells (human kidney epithelial cells), BHK cells (baby hamster kidney cells),
and Vero-SLAM cells (African green monkey kidney cells) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (GIBCO, Invitrogen) supplemented with 10% fetal bovine serum and antibiotics in 5%
CO2. The Vero-SLAM culture medium was supplemented with Geneticin. The WTFb strain for cotton rat
infection was described previously 80. Wild-type MV strain G954 (genotype B3.2) was isolated in Gambia
in 1993 (BB-0033-00053) (81). All virus strains were propagated and titrated in Vero SLAM cells.
-Gal complementation-based fusion assay. The -galactosidase (-gal) complementation-based
fusion assay was performed as described previously (46, 82). Briefly, 293T cells transiently transfected
with SLAM and the omega reporter subunit were incubated with cells coexpressing viral glycoproteins
(MV H and MV F) and the alpha reporter subunit.
ELISA. For biodistribution studies, each organ was weighed and mixed in phosphate-buffered saline
(PBS) (1:1, wt/vol) using an Ultra Turrax homogenizer. Samples were then treated with acetonitrile–1%
trifluoroacetic acid (1:4, vol/vol) for 1 h on a rotor at 4°C and then centrifuged for 10 min at 6,000  g.
Supernatant fluids were collected, and the peptide concentration was determined using an enzyme-
linked immunosorbent assay (ELISA). MaxiSorp 96-well plates (Nunc) were coated overnight with purified
rabbit anti-MV F HRC antibodies (5 g/ml) in carbonate-bicarbonate buffer pH 7.4. Plates were washed
twice using PBS, followed by incubation with 3% bovine serum albumin (BSA) in PBS (blocking buffer)
for 30 min. The blocking buffer was replaced with 2 dilutions of each sample in 3% PBS-BSA in duplicate
and incubated for 90 min at room temperature (RT). After multiple washes in PBS, the peptide was
detected using a horseradish peroxidase (HRP)-conjugated rabbit custom-made anti-MV F HRC antibody
(1:1,500) in blocking buffer for 2 h at RT. HRP activity was recorded as absorbance at 492 nm on the
SigmaFast o-phenylenediamine dihydrochloride (OPD) substrate system (Sigma-Aldrich) after adding the
stop solution. Standard curves were established for each peptide (using the same ELISA conditions as for
the test samples), and the detection limit was determined to be 0.15 nM.
HAE cultures. The EpiAirway AIR-100 system (MatTek Corporation) used in these experiments
consists of normal, human-derived tracheobronchial epithelial cells that have been cultured to form a
highly differentiated mucociliary epithelium. Upon receipt from the manufacturer, human airway epi-
thelium (HAE) cultures were handled as previously described (47, 48, 83); we have used HAE for
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assessment of entry inhibitors (47–51). To assess the potential for delivery of the HRC peptides via the
airway to the basolateral compartment, 20 l of 250 M peptide inhibitor was applied to the apical
surface. At the indicated time points, aliquots of the basolateral supernatant fluid were collected to
quantify the amount of peptide delivered to the basolateral reservoir. The 20 l of 250 M peptide
inhibitor in the 1 ml of reservoir would have had an upper-limit final concentration of 5 M.
Biodistribution analysis and infection of CR. Inbred cotton rats (CR) (Sigmodon hispidus) were
purchased from Harlan Laboratories, Inc., Indianapolis, IN, USA. Both male and female cotton rats aged
5 to 7 weeks were used. For biodistribution experiments in CR, the animals received the indicated
peptides (6 mg/kg) intranasally (i.n.) in 100 l of water for injection. After 8 h, blood was collected by
intracardiac puncture in EDTA Vacutainer tubes, and plasma was conserved at 	20°C until use in ELISA.
Organs from each animal were collected, snap-frozen in liquid nitrogen, and conserved at 	80°C. For i.n.
infection, 105 TCID50 of MV WTFb was inoculated in phosphate-buffered saline to isoflurane-anesthetized
cotton rats in a volume of 100 l. To evaluate the effect of HRC peptides, animals were inoculated i.n. with
peptide (5 mg/kg in 100 l of water) at 24 h and 12 h before infection. Four days after infection, the animals
were asphyxiated using CO2, and their lungs were collected and weighed. Lung tissue was minced with
scissors and homogenized with a Dounce glass homogenizer. Serial 10-fold dilutions of supernatant fluids
were assessed for the presence of infectious virus in a 48-well plates using cytopathic effect (CPE) in Vero
SLAM cells as the endpoint. Plates were scored for CPE microscopically after 7 days. The amounts of virus in
inocula were expressed as fold dilutions that resulted in the infection of 50% of inoculated tissue culture
monolayers (TCID50). The TCID50 was calculated as described previously (84). The animal experiments were
approved by the Institutional Animal Care and Use Committee of Ohio State University.
Infection of mice. Three- to 4-week-old SLAMIFNARKO mice, which are highly susceptible to MV
infection (29, 45), were infected i.n., with 10 l of DMEM containing 104 PFU of MV. Animals were treated
with HRC5 or HRC6 i.n. (6 mg/kg) at 24 h and 4 h before infection (10 l of peptide-containing vehicle).
The mock-infected group received only the vehicle at the same time (Aguettant water containing 10%
DMSO). All animals were observed daily for 28 days, and those showing clinical signs (neurological
symptoms, ataxia, or lethargy) were euthanized. The protocol was approved by the Regional Ethical
Committee (CECCAPP protocol no. ENS-2011-003 and ENS-2012-041).
Statistical analysis. Data are expressed as mean and standard deviation (SD). Statistical analyses
were performed using a Mann-Whitney U test, a Mantel-Cox test, and a Tukey range test with GraphPad
Prism 5 software.
Data analysis. Fitting of the equations mentioned in this article to the experimental data was done
by nonlinear regression using GraphPad Prism. Error bars on data presentation represent the SD or
standard error (SE).
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